Praxis Precision Medicines, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed February 28, 2022. This is an annual report, and the provided filing text does not give standalone fourth-quarter financial results.
Business context
Praxis is a clinical-stage biopharmaceutical company developing central nervous system therapies based on genetic insights and neuronal excitation-inhibition biology. Its portfolio spans psychiatry, movement disorders, epilepsy and exploratory indications. It had three clinical-stage candidates at year-end and no approved products or product-sale revenue.
Financial performance and liquidity
| Metric (USD millions, except per-share data) | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | 120.3 | 45.0 |
| General and administrative expense | 47.1 | 17.0 |
| Total operating expenses | 167.3 | 62.0 |
| Net loss | 167.1 | 61.8 |
| Net loss per share, basic and diluted | $3.94 | $7.86 |
| Net cash used in operating activities | 124.6 | 52.6 |
| Cash and cash equivalents | 138.7 | 296.6 |
| Marketable securities | 137.2 | — |
| Total assets | 292.7 | 303.2 |
| Total liabilities | 41.9 | 15.7 |
| Stockholders’ equity | 250.8 | 287.5 |
Net loss and operating cash use increased as development programs, clinical-trial activity and staffing expanded. Research and development expense rose by $75.3 million; general and administrative expense rose by $30.1 million. Stock-based compensation was $22.7 million, versus $5.2 million in 2020. No operating margins are meaningful because the company has no revenue.
Cash, cash equivalents and marketable securities totaled $275.9 million at year-end. Financing activities provided $107.6 million net, principally from a May 2021 follow-on offering and at-the-market sales; investing activities used $140.5 million, primarily for marketable securities purchases. The company reported no debt in the provided financial statements. Operating lease liabilities totaled $4.3 million; remaining lease payments were $5.2 million. Management estimated available funds would support operating expenses and capital expenditures into the second quarter of 2023, subject to assumptions that may prove inaccurate.
Portfolio, outlook and material developments
- PRAX-114: In Phase 2/3 and Phase 2 placebo-controlled MDD studies, with a Phase 2 PTSD study initiated. Management expected MDD readouts in Q2 and mid-2022, respectively, and PTSD results in the second half of 2022. Earlier Phase 2a depression results were open-label and involved small cohorts; they do not establish efficacy in controlled trials. Somnolence, headache and dizziness were among reported adverse events.
- PRAX-944: In development for essential tremor (ET) and Parkinson’s disease (PD). Management expected Phase 2a ET results in Q2 2022 and Phase 2b Essential1 results in the second half of 2022; a Phase 2 PD study was planned for Q2 2022. ET evidence cited in the filing was preliminary and included open-label observations.
- PRAX-562: Management expected to begin a Phase 2 study in rare pediatric developmental and epileptic encephalopathies and a proof-of-concept study in rare adult cephalgias during 2022. It also reported positive biomarker observations from healthy-volunteer Phase 1 work; clinical benefit in patients remained unproven.
- PRAX-222: An antisense candidate for SCN2A gain-of-function epilepsy. Praxis exercised its Ionis license option in January 2022 and paid a $2.0 million fee; it expected to begin a seamless clinical study in Q2 2022. PRAX-628 was nominated for focal epilepsy in Q4 2021 and remained preclinical.
- Management anticipated multiple clinical readouts and a fourth clinical development program in 2022, while expecting expenses and operating losses to increase. These are forward-looking plans, not guaranteed outcomes.
Praxis raised approximately $98.4 million net from its May 2021 follow-on offering and approximately $7.0 million net through its ATM program by year-end. Common shares outstanding increased from 38.3 million to 45.3 million during 2021. The company said it would need substantial additional funding and had no committed external source of capital.
Risks, contingencies and unusual items
- Clinical and regulatory outcomes are uncertain; candidates may fail, cause unacceptable adverse effects, or require additional trials, delaying approval and increasing costs.
- Praxis depends on third-party manufacturers, research organizations and collaborators. Capital needs, possible future dilution, licensing obligations and competition are material risks; COVID-19 had slowed enrollment in some studies, although the company said it had not significantly changed overall trial timelines.
- Potential contingent license costs include up to $33.0 million in Purdue development and sales milestones, Ionis milestones and royalties, and a conditional $3.0 million RogCon milestone plus profit sharing. These amounts are generally contingent on future milestones or sales and were not recorded as liabilities when the triggering events had not occurred.
- Praxis disclosed receiving a May 2020 cease-and-desist letter from Sage Therapeutics alleging improper access to confidential information relating to PRAX-114. Praxis said it believed the claims lacked merit and intended to defend its position. Separately, it reported no material legal proceedings currently pending or threatened.
- The independent auditor issued an unqualified opinion on the financial statements and internal controls. The audit identified accrued and prepaid PRAX-114 Aria and Acapella trial costs as a critical audit matter because estimating vendor services performed and related costs required significant judgment. Management reported effective disclosure controls and internal control over financial reporting.
Most important facts for investors to verify
- Final, placebo-controlled efficacy and safety results for PRAX-114, PRAX-944 and PRAX-562, compared with the filing’s preliminary or open-label observations.
- Whether the projected cash runway into Q2 2023 remains realistic given operating cash use, trial expansion and the timing or terms of future financing.
- Current share count, subsequent equity issuance and potential dilution, including remaining ATM capacity and outstanding equity awards.
- Terms, milestones, royalties and any subsequent payments under the Ionis, RogCon and Purdue arrangements, as well as developments concerning Sage’s allegation.
- Whether trial timelines, enrollment, adverse-event findings and third-party supply arrangements have changed since the filing.